Comparison of proximal and distal gastric neuroendocrine carcinoma based on SEER database.
Competing risk analysis
Gastric neuroendocrine carcinoma
Location
Nomogram
Prognosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
04
07
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The occurrence of gastric neuroendocrine carcinoma (GNEC) is on the rise, and its prognosis is extremely poor. We compared survival outcomes between distal and proximal GNEC and developed a nomogram incorporating tumor site to enhance personalized management for patients with GNEC. 1807 patients were divided into DGNEC and PGNEC groups. We performed analyses by using propensity score matching (PSM) and Fine-Gray competing risk methods. A predictive nomogram for the prognosis of GNEC was constructed and validated. The cumulative incidence of cancer-specific death (CSD) in the DGNEC group was lower than that in the PGNEC group. Subgroup analysis showed lower CSD of DGNEC in males, females, tumor sizes (≤ 2 cm, 2 < tumor size ≤ 5 cm, > 5 cm, and unknown), grade stage I-II, and AJCC stage I-III, chemotherapy or no chemotherapy, surgery or no surgery groups (P < 0.05). Multivariate analysis revealed a significant association between PGNEC and CSD (HR, 1.4; 95% CI 1.13-1.73; P = 0.02). The independent predictors of CSD in patients with GNEC were primary site, gender, age, tumor size, AJCC stage, T stage, N stage, grade stage, and surgery. A predictive model based on multivariate analysis was constructed to estimate the probability of CSD at 1-, 3-, and 5-year. The calibration curves demonstrated excellent consistency between the predicted and observed probabilities of CSD. Patients with DGNEC have a better prognosis than those with PGNEC. The model exhibits strong predictive capability for these patients.
Identifiants
pubmed: 39472636
doi: 10.1038/s41598-024-76689-z
pii: 10.1038/s41598-024-76689-z
doi:
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
25956Subventions
Organisme : Hangzhou Agricultural and Social Development Research Guide Project
ID : 20220919Y116
Organisme : Zhejiang Traditional Medicine and Technology Program
ID : 2024ZL625
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA A Cancer J. Clin. 73, 17–48 (2023).
doi: 10.3322/caac.21763
Hu, P. et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 23, 591–599 (2020).
pubmed: 32026156
pmcid: 7305263
doi: 10.1007/s10120-020-01046-8
Cao, L.-L. et al. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database. Eur. J. Surg. Oncol. 44, 1628–1633 (2018).
pubmed: 29983275
doi: 10.1016/j.ejso.2018.01.082
Matsueda, K. et al. Endoscopic features of gastric neuroendocrine carcinoma. J. Gastro Hepatol. 38, 1808–1817 (2023).
doi: 10.1111/jgh.16309
Zhao, Q., Chen, K., Tong, W., Ge, C. & Zhao, D. Gastric cancer in proximal site exerts poorer survival outcome with divergent genetic features than distal site. Comput. Biol. Chem. 88, 107360 (2020).
pubmed: 32841839
doi: 10.1016/j.compbiolchem.2020.107360
Hirabayashi, M., Georges, D., Clifford, G. M. & de Martel, C. Estimating the global burden of Epstein-Barr virus-associated gastric cancer: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 922-930.e21 (2023).
pubmed: 35963539
doi: 10.1016/j.cgh.2022.07.042
Fang, C. et al. Risk factors of early proximal gastric carcinoma in Chinese diagnosed using WHO criteria. J. Dig. Dis. 16, 327–336 (2015).
pubmed: 25754397
doi: 10.1111/1751-2980.12240
Lordick, F. et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005–1020 (2020).
doi: 10.1016/j.annonc.2022.07.004
Network, T. C. G. A. R. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
doi: 10.1038/nature20805
Panzuto, F. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3. J. Neuroendocrinol. 35, e13306 (2023).
pubmed: 37401795
doi: 10.1111/jne.13306
de Jongh, C. et al. Distal versus total D2-gastrectomy for gastric cancer: a secondary analysis of surgical and oncological outcomes including quality of life in the multicenter randomized LOGICA-trial. J. Gastrointest. Surg. 27, 1812–1824 (2023).
pubmed: 37340107
pmcid: 10511620
doi: 10.1007/s11605-023-05683-z
Jiang, Y. et al. Surgical and oncological outcomes of distal gastrectomy compared to total gastrectomy for middle-third gastric cancer: A systematic review and meta-analysis. Oncol. Lett. https://doi.org/10.3892/ol.2022.13411 (2022).
doi: 10.3892/ol.2022.13411
pubmed: 36589662
pmcid: 9773325
Yang, W.-J. et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J. Gastroenterol. 29, 2452–2468 (2023).
pubmed: 37179585
pmcid: 10167900
doi: 10.3748/wjg.v29.i16.2452
Zhao, L. et al. Clinicopathological characteristics and prognosis of proximal and distal gastric cancer during 1997–2017 in China National Cancer Center. J. Oncol. 2019, 1–13 (2019).
Nakao, T. et al. Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan. Int. J. Clin. Oncol. 26, 378–386 (2020).
pubmed: 33151441
doi: 10.1007/s10147-020-01820-9
Petrelli, F. et al. Prognostic role of primary tumor location in non-metastatic gastric cancer: A systematic review and meta-analysis of 50 studies. Ann. Surg. Oncol. 24, 2655–2668 (2017).
pubmed: 28299508
doi: 10.1245/s10434-017-5832-4
Yang, Y. et al. Microbiota and metabolites alterations in proximal and distal gastric cancer patients. J. Transl. Med. 20, 439 (2022).
pubmed: 36180919
pmcid: 9524040
doi: 10.1186/s12967-022-03650-x
Du, D. et al. De-escalating chemotherapy for stage I-II gastric neuroendocrine carcinoma? A real-world competing risk analysis. World J. Surg. Oncol. 21, 142 (2023).
pubmed: 37149679
pmcid: 10163728
doi: 10.1186/s12957-023-03029-2
Filleron, T., Laplanche, A., Boher, J.-M. & Kramar, A. An R function to non-parametric and piecewise analysis of competing risks survival data. Comput. Methods Progr. Biomed. 100, 24–38 (2010).
doi: 10.1016/j.cmpb.2010.02.004
Zhang, Z., Geskus, R. B., Kattan, M. W., Zhang, H. & Liu, T. Nomogram for survival analysis in the presence of competing risks. Ann. Transl. Med. 5, 403–403 (2017).
pubmed: 29152503
pmcid: 5673789
doi: 10.21037/atm.2017.07.27
Song, X., Xie, Y., Zhu, Y. & Lou, Y. Is iobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis. BMC Cancer 22, 541 (2022).
pubmed: 35562694
pmcid: 9102677
doi: 10.1186/s12885-022-09634-w
Omori, T. et al. Safety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study). Langenbecks Arch. Surg. 407, 3387–3396 (2022).
pubmed: 36227384
doi: 10.1007/s00423-022-02680-9
Zhao, Y., Yang, R. & Lu, H. A gastric neuroendocrine carcinoma with good prognosis after chemotherapy combined with immunotherapy: A case report (CARE-compliant). Medicine 102, e36568 (2023).
pubmed: 38115336
pmcid: 10727576
doi: 10.1097/MD.0000000000036568
Song, X., Xie, Y. & Lou, Y. A novel nomogram and risk stratification system predicting the cancer-specific survival of patients with gastric neuroendocrine carcinoma: a study based on SEER database and external validation. BMC Gastroenterol. 23, 238 (2023).
pubmed: 37452300
pmcid: 10347809
doi: 10.1186/s12876-023-02875-4
Lin, J. et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw. Open 4, e2114180 (2021).
pubmed: 34313744
pmcid: 8317013
doi: 10.1001/jamanetworkopen.2021.14180
Li, Z. et al. Better prognosis of gastric neuroendocrine carcinoma than gastric adenocarcinoma among whites in the United States: A propensity score matching analysis based on SEER. Curr. Oncol. 29, 4879–4892 (2022).
pubmed: 35877247
doi: 10.3390/curroncol29070387
Xu, B., Chu, Y., Hu, Q. & Song, Q. The clinicopathological features and overall survival of patients with gastric neuroendocrine carcinoma. Technol. Cancer Res. Treat. 20, 153303382110553 (2021).
doi: 10.1177/15330338211055340
de Jesus, V. H. F. et al. Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. J. Gastrointest. Oncol. 10, 1110–1119 (2019).
pubmed: 31949928
doi: 10.21037/jgo.2019.10.04
Sorbye, H. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J. Neuroendocrinol. 35, e13306 (2023).
doi: 10.1111/jne.13249
Thornblade, L. W. et al. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?. Surgery 169, 1417–1423 (2021).
pubmed: 33637345
doi: 10.1016/j.surg.2021.01.026
Liu, J. et al. Clinicopathological features and postoperative survival analysis of gastric carcinoma with neuroendocrine differentiation. J. Oncol. 2022, 1–9 (2022).
doi: 10.1155/2022/3658334
Chen, H., Shu, M., Chen, S., Xue, L. & Lin, Y. Clinicopathological features and lymph node metastatic patterns of gastric mixed adenoneuroendocrine carcinoma. Histol. Histopathol. 2019, 373–379 (2019).
Chen, J., Wang, A., Ji, K., Bu, Z. & Ji, J. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study. BMC Cancer 20, 777 (2020).
pubmed: 32811471
pmcid: 7437076
doi: 10.1186/s12885-020-07281-7
Ma, F. et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J. Cancer Res. Clin. Oncol. 146, 2135–2142 (2020).
pubmed: 32306127
doi: 10.1007/s00432-020-03214-w
Bozkaya, Y., Ozdemir, N., Colak, A. & Zengin, N. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy. J. BUON 22, 919–925 (2017).
pubmed: 29155521
Lin, J.-P. et al. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas. Br. J. Surg. 107, 1163–1170 (2020).
pubmed: 32323879
doi: 10.1002/bjs.11608
Branagan, G., Chave, H., Fuller, C., McGee, S. & Finnis, D. Can magnetic resonance imaging predict circumferential margins and TNM stage in rectal cancer?. Dis. Colon Rectum 47, 1317–1322 (2004).
pubmed: 15484345
doi: 10.1007/s10350-004-0594-z
Chou, J. F. et al. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer. Cancer 116, 2560–2570 (2010).
pubmed: 20499400
doi: 10.1002/cncr.25032
Balde, A. I. et al. Propensity score analysis of recurrence for neutrophil-to-lymphocyte ratio in colorectal cancer. J. Surg. Res. 219, 244–252 (2017).
pubmed: 29078889
doi: 10.1016/j.jss.2017.05.109
Okumura, T. et al. Clinical analysis of extrapulmonary neuroendocrine carcinoma: A retrospective and single institution experience. Chemotherapy 68, 87–94 (2022).
pubmed: 36327945
doi: 10.1159/000527377
van der Veen, A. et al. Management of resectable esophageal and gastric (mixed adeno) neuroendocrine carcinoma: A nationwide cohort study. Eur. J. Surg. Oncol. 44, 1955–1962 (2018).
pubmed: 30201419
doi: 10.1016/j.ejso.2018.07.058
Chang, L., Zhang, X., Li, J. & Li, Q. Clinicopathological characteristics, survival and prognostic factors in gastrointestinal large cell neuroendocrine carcinoma. Am. J. Clin. Oncol. 47, 363–372 (2024).
pubmed: 38629640
pmcid: 11265646
doi: 10.1097/COC.0000000000001104
Misirlioglu, H. C. et al. Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. Asian Pac. J. Cancer Prev. 15, 8871–8876 (2014).
pubmed: 25374221
doi: 10.7314/APJCP.2014.15.20.8871